Curasight Updates Phase I Trial Protocol for Glioblastoma Treatment
Curasight A/S announced a protocol amendment for its ongoing Phase I uTREAT® trial evaluating the treatment in glioblastoma patients. The change aims to optimize the study design and gather broader data for future research.
Curasight A/S announced on July 27, 2026, an amendment to the protocol for its ongoing Phase I clinical trial investigating uTREAT®. The trial focuses on patients diagnosed with glioblastoma, an aggressive form of brain cancer.
The proposed amendment has been submitted to relevant regulatory authorities for approval. Its primary goal is to refine the study's design and expand the scope of gathered information, which will inform the planning of subsequent trial phases.
A key modification includes the administration of uTREAT® without blood-brain barrier disruption via mannitol for newly enrolled patients. This adjustment is intended to streamline the therapeutic process and potentially enhance the therapeutic benefit.
Glioblastoma remains a challenging diagnosis with limited treatment options. The development of novel therapeutic strategies is crucial for improving patient outcomes in this area of oncology.